- Our Company
- News & Events
- Contact Us
Recently published in The Lancet Oncology, results from the plasmaMATCH trial of women with advanced breast cancer demonstrate that the Guardant360 liquid biopsy accurately identifies actionable mutations in genes such as HER2 and AKT1 and can guide appropriate treatment selection. https://lnkd.in/guTdfVf
Visit us online @ guardanthealthamea.com to find out more about Guardant360®, the global leader in liquid biopsy. If you have any queries, send us an email at email@example.com or contact us on WhatsApp: +65 8940 0360.
Guardant360®. Test. Take Action.